Previous reports have also described such immune contexture for ARID1A mutated tumours without specifying the heterozygosity [27,28], but whether this condition could be a biomarker of immunotherapy benefit in solid tumours is still debated in the literature [29,30]. This evidence concerns the gene ARID1A and neoplasm.